CORRESP Filing
ImageneBio, Inc.
Date: June 10, 2025 · CIK: 0001835579 · Accession: 0001140361-25-022073
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-285881
Letter
VIA EDGAR Office of Life Sciences Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street NE Washington, D.C. 20549-3628 Attention: Requested Date: June 11, 2025 Requested Time: 4:15 p.m. Eastern Time
Re:
Dear Ms. Torney, Ms. Dicker, Mr. Crawford and Mr. Campbell:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “ Act ”), Ikena Oncology, Inc. (the “ Company ”) hereby requests that the effective date of the above-referenced registration statement (the “ Registration Statement ”) be accelerated to June 11, 2025, at 4:15 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.
Once the Registration Statement is effective, please orally confirm the event with our counsel, Goodwin Procter LLP by calling Stephanie Richards at (617) 570-1927. We also respectfully request that a copy of the written order from the Securities and Exchange Commission verifying the effective time and date of the Registration Statement be sent to our counsel, Goodwin Procter LLP, Attention: Stephanie Richards, by email to srichards@goodwinlaw.com .
If you have any questions regarding this request, please contact Stephanie Richards of Goodwin Procter LLP at (617) 570-1927.
Sincerely,
Ikena Oncology, Inc.
Show Raw Text
CORRESP 1 filename1.htm Ikena Oncology, Inc. 645 Summer Street, Suite 101 Boston, MA 02210 June 10, 2025 VIA EDGAR Office of Life Sciences Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street NE Washington, D.C. 20549-3628 Attention: Ms. Christine Torney Ms. Lynn Dicker Mr. Daniel Crawford Mr. Alan Campbell Re: Ikena Oncology, Inc. Acceleration Request for Registration Statement on Form S-4 File No. 333-285881 Requested Date: June 11, 2025 Requested Time: 4:15 p.m. Eastern Time Dear Ms. Torney, Ms. Dicker, Mr. Crawford and Mr. Campbell: Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “ Act ”), Ikena Oncology, Inc. (the “ Company ”) hereby requests that the effective date of the above-referenced registration statement (the “ Registration Statement ”) be accelerated to June 11, 2025, at 4:15 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act. Once the Registration Statement is effective, please orally confirm the event with our counsel, Goodwin Procter LLP by calling Stephanie Richards at (617) 570-1927. We also respectfully request that a copy of the written order from the Securities and Exchange Commission verifying the effective time and date of the Registration Statement be sent to our counsel, Goodwin Procter LLP, Attention: Stephanie Richards, by email to srichards@goodwinlaw.com . If you have any questions regarding this request, please contact Stephanie Richards of Goodwin Procter LLP at (617) 570-1927. Sincerely, Ikena Oncology, Inc. /s/ Mark Manfredi Mark Manfredi, Ph.D. President and Chief Executive Officer cc: Stephanie Richards, Goodwin Procter LLP John T. Haggerty, Goodwin Procter LLP Richard A. Hoffman, Goodwin Procter LLP Amanda Gill, Goodwin Procter LLP Lauren Visek, Goodwin Procter LLP